Barclays’s Cidara Therapeutics CDTX Stock Holding History

Barclays’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-75,000	Closed	-$3.65M	–	5508
2025 Q2	$3.65M	Buy	+75,000	New	+$1.8M	﹤0.01%	2367

Barclays's CDTX Position: Q1 2026 in Review

Barclays sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 78,322 shares — an estimated $17.3M sold.

Barclays first reported a position in CDTX in Q2 2015 and held it in 22 quarters. The position peaked at $17.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Barclays reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Barclays sold 78,322 Cidara Therapeutics shares in Q1 2026, an estimated $17.3M.
Barclays first reported a position in Cidara Therapeutics in Q2 2015 and held it in 22 quarters.
Barclays's Cidara Therapeutics position peaked at $17.3M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.